Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | CRHBP | P24387 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4864150 | 0.91 | KMT2A (0.57) | KMT2AMEN1CRHBPCRHR2POLB | |
| SCHEMBL4866457 | 0.90 | KMT2A (0.57) | KMT2AMEN1CRHBPCRHR2POLB | |
| SCHEMBL4870059 | 0.88 | USP2 (0.45) | KMT2AMEN1CRHBPCRHR2MAPT | |
| SCHEMBL4864075 | 0.84 | USP2 (0.45) | KMT2AMEN1CRHBPCRHR2MAPT | |
| SCHEMBL4867553 | 0.84 | USP2 (0.45) | KMT2AMEN1CRHBPCRHR2MAPT | |
| SCHEMBL4865737 | 0.84 | KMT2A (0.56) | KMT2AMEN1CRHBPCRHR2POLB | |
| SCHEMBL4870374 | 0.83 | SMN1; SMN2 (0.43) | MAPTTP53P2RY1 | |
| SCHEMBL4867565 | 0.82 | ALDH1A1 (0.47) | KMT2AMEN1CRHBPCRHR2POLB | |
| SCHEMBL4867889 | 0.81 | SMN1; SMN2 (0.43) | MAPTTP53P2RY1 | |
| SCHEMBL4866466 | 0.81 | SMN1; SMN2 (0.43) | MAPTTP53P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351709-B2 | Estrogen receptor ligands | WYETH (US) | 2008-04-01 | — | — | US | disclosed |
| US-20060019961-A1 | Estrogen receptor ligands | WYETH | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019961-A1 | Estrogen receptor ligands | GPER1, ESR2, ESR1 | KMT2A 2436/4885MEN1 4543/4885CRHBP 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.